Introduction of mycophenolate mofetil and cyclosporin reduction in children with chronic transplant nephropathy

Pediatric Transplantation

Volumn 5, Issue 4, 2001, Pages 302-309

  David Neto, E ^a   Araujo, L M P ^a   Lemos, F C ^a   David, D S R ^a   Mazzucchi, E ^a   Nahas, W C ^a   Arap, S ^a   Ianhez, L E ^a  

^a NONE   (Brazil)

Author keywords

Children; Chronic rejection; Chronic transplant nephropathy; Cyclosporin A nephrotoxicity; Kidney transplantation; Mycophenolate mofetil

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT PRESERVATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; NEPHROTOXICITY; TREATMENT OUTCOME;

CREATININE; CYCLOSPORINE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; LINEAR MODELS; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 0034939094     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2001.00007.x     Document Type: Article

References (23)

1. Mycophenolate mofetil slows the decline of renal function in patients with biopsy-proven chronic rejection: A collaborative pilot study
2. Chronic renal allograft rejection: No response to mycophenolate mofetil
3. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function
4. Treatment of chronic rejection in renal transplantation by mycophenolate mofetil (MMF): A preliminary report of six-month experience
5. A novel approach to the treatment of chronic allograft nephropathy
6. Adverse effects of mycophenolate mofetil in pediatric renal transplant recipients with presumed chronic rejection
7. The replacement of azathioprine by mycophenolate mofetil in pediatric patients with specific risks in renal transplantation
8. Conversion from azathioprine to mycophenolate mofetil in pediatric renal transplant recipients with chronic rejection
9. The Banff 97 working classification of renal allograft pathology
10. Impact of cyclosporin A pharmacokinetics on the presence of side effects in pediatric renal transplantation
11. A simple estimate of glomerular filtration rate in adolescent boys
12. The 1997 annual renal transplantation in children report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)
13. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction
14. Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients
15. Is the improvement of renal function in chronic allograft nephropathy, after MMF introduction, related to cyclosporin A reduction? 18th American Society of Transplantation Annual Meeting
16. Comparison of three immunosuppressive regimens in cadaver renal transplantation: Long-term cyclosporine, short-term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine
17. A controlled trial of cyclosporine in renal transplantation with conversion to azathioprine and prednisolone after three months
18. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial
19. Mycophenolate mofetil in cadaveric renal transplantation
20. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection
21. Mycophenolate mofetil attenuates renal injury in the rat remnant kidney
22. Sequential cytokine expression in renal allografts in rats immunosuppressed with maintenance cyclosporine or mycophenolate mofetil
23. Inhibition of early chronic rejection in rat aortic allografts by mycophenolate mofetil (RS61443)